BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25210858)

  • 1. Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.
    Cioffi CL; Dobri N; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DM; Golden KC; Zhu L; Kitchen DB; Barnes KD; Racz B; Qin Q; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K
    J Med Chem; 2014 Sep; 57(18):7731-57. PubMed ID: 25210858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.
    Dobri N; Qin Q; Kong J; Yamamoto K; Liu Z; Moiseyev G; Ma JX; Allikmets R; Sparrow JR; Petrukhin K
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):85-95. PubMed ID: 23211825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.
    Racz B; Varadi A; Kong J; Allikmets R; Pearson PG; Johnson G; Cioffi CL; Petrukhin K
    J Biol Chem; 2018 Jul; 293(29):11574-11588. PubMed ID: 29871924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.
    Cioffi CL; Muthuraman P; Raja A; Varadi A; Racz B; Petrukhin K
    J Med Chem; 2020 Oct; 63(19):11054-11084. PubMed ID: 32878437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.
    Cioffi CL; Racz B; Freeman EE; Conlon MP; Chen P; Stafford DG; Schwarz DM; Zhu L; Kitchen DB; Barnes KD; Dobri N; Michelotti E; Cywin CL; Martin WH; Pearson PG; Johnson G; Petrukhin K
    J Med Chem; 2015 Aug; 58(15):5863-88. PubMed ID: 26181715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.
    Cioffi CL; Racz B; Varadi A; Freeman EE; Conlon MP; Chen P; Zhu L; Kitchen DB; Barnes KD; Martin WH; Pearson PG; Johnson G; Blaner WS; Petrukhin K
    J Med Chem; 2019 Jun; 62(11):5470-5500. PubMed ID: 31079449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Levels of Retinol-Binding Protein 4 and Vitamin A in Healthy Subjects, Stargardt Disease, and Geographic Atrophy Patients.
    Janeschitz-Kriegl L; Cattaneo M; Scholl HPN
    Ophthalmic Res; 2022; 65(3):351-360. PubMed ID: 35108705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo.
    Motani A; Wang Z; Conn M; Siegler K; Zhang Y; Liu Q; Johnstone S; Xu H; Thibault S; Wang Y; Fan P; Connors R; Le H; Xu G; Walker N; Shan B; Coward P
    J Biol Chem; 2009 Mar; 284(12):7673-80. PubMed ID: 19147488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
    Wang Y; Connors R; Fan P; Wang X; Wang Z; Liu J; Kayser F; Medina JC; Johnstone S; Xu H; Thibault S; Walker N; Conn M; Zhang Y; Liu Q; Grillo MP; Motani A; Coward P; Wang Z
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2885-91. PubMed ID: 24835984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.
    Cioffi CL; Raja A; Muthuraman P; Jayaraman A; Jayakumar S; Varadi A; Racz B; Petrukhin K
    J Med Chem; 2021 Jul; 64(13):9010-9041. PubMed ID: 34138572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey.
    Racz B; Varadi A; Pearson PG; Petrukhin K
    PLoS One; 2020; 15(1):e0228291. PubMed ID: 31978148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-resolved fluorescence resonance energy transfer and surface plasmon resonance-based assays for retinoid and transthyretin binding to retinol-binding protein 4.
    Sharif O; Hu H; Klock H; Hampton EN; Nigoghossian E; Knuth MW; Matzen J; Anderson P; Trager R; Uno T; Glynne RJ; Azarian SM; Caldwell JS; Brinker A
    Anal Biochem; 2009 Sep; 392(2):162-8. PubMed ID: 19482004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic Mice Over-Expressing RBP4 Have RBP4-Dependent and Light-Independent Retinal Degeneration.
    Du M; Phelps E; Balangue MJ; Dockins A; Moiseyev G; Shin Y; Kane S; Otalora L; Ma JX; Farjo R; Farjo KM
    Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4375–4383. PubMed ID: 28813718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of an allosteric model to describe the interactions among retinol binding protein 4, transthyretin, and small molecule retinol binding protein 4 ligands.
    Coward P; Conn M; Tang J; Xiong F; Menjares A; Reagan JD
    Anal Biochem; 2009 Jan; 384(2):312-20. PubMed ID: 18952041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of phenylpyrrolidine derivatives as a novel class of retinol binding protein 4 (RBP4) reducers.
    Nakamura S; Kamaura M; Akao Y; Nakamura N; Mizukami A; Goto A; Furuyama N; Cho N; Kasai S
    Bioorg Med Chem; 2022 Jan; 54():116553. PubMed ID: 34953340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 Fatty Acids Supplementation: Therapeutic Potential in a Mouse Model of Stargardt Disease.
    Prokopiou E; Kolovos P; Kalogerou M; Neokleous A; Nicolaou O; Sokratous K; Kyriacou K; Georgiou T
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2757-2767. PubMed ID: 29860462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development.
    Kim N; Priefer R
    Eur J Med Chem; 2021 Dec; 226():113856. PubMed ID: 34547506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel lipofuscin bisretinoids prominent in human retina and in a model of recessive Stargardt disease.
    Wu Y; Fishkin NE; Pande A; Pande J; Sparrow JR
    J Biol Chem; 2009 Jul; 284(30):20155-66. PubMed ID: 19478335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human plasma retinol-binding protein (RBP4) is also a fatty acid-binding protein.
    Perduca M; Nicolis S; Mannucci B; Galliano M; Monaco HL
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Apr; 1863(4):458-466. PubMed ID: 29414511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Retinol Binding Protein 4 and
    Chou HD; Hwang YS; Chen KJ; Wu WC; Liu L; Ou ST; Liao W; Wang CC; Lin T; Lai CC
    Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.